NCT01928914 - Tafenoquine Thorough QTc Study in Healthy Subjects | Biotech Hunter

Enrollment

260

Participants

Timeline

Start Date

July 26, 2011

Primary Completion Date

June 4, 2012

Study Completion Date

June 4, 2012

Conditions

Malaria, Vivax

Interventions

DRUG

Tafenoquine 300mg

Single dose of Tafenoquine give on Day 3 only

DRUG

Tafenoquine 600mg

Single dose of Tafenoquine given on Day 3 only

DRUG

Tafenoquine 1200mg

400mg Dose of Tafenoquine given on each of the three consecutive dosing days

DRUG

moxifloxacin

moxifloxacine given on Day 3 only

DRUG

Placebo for Tafenoquine

Placebo given on all three days to all groups except for group 5 on Day 3

DRUG

Placebo for moxifloxaxin

Placebo for moxifloxacin, given to all groups on all days except for Group 3 on Day 3

Trial Locations (2)

GSK Investigational Site, Baltimore

GSK Investigational Site, Culver City